Obermatt
See Similar Stocks →

CRISPR Therapeutics

NMQ:CRSP · CH0334081137
BiotechnologySmall

360

22
Medium confidence — indicative
Profit price35
Owner Earnings Yield1
Dividend Yield1
Price/Sales8
Price/Book34
Return on Capital56
Cash Return on Capital36
Return on Equity42
Profit margins19
Accruals41
Owner Earnings Margin1
Sales growth98
Profit growth8
Reinvestment80
Price momentum65
Debt load41
Refinancing29
Debt Payback1
Liquidity23
Analyst ratings11
Opinion Changes30
Price Target Upside68
Market mood45
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

CRISPR Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2013
Employees306
Websitecrisprtx.com
ISINCH0334081137
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health Care
Themes
ImmunologyCardiovascularHematologyGenetic DisorderDiabetesStem Cell TherapyOncologyGenetics

Description

CRISPR Therapeutics AG, a leading biopharmaceutical company, focuses on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely alt…

Analysis

Middle-of-the-road

CRISPR Therapeutics AG is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
11
2026

All-time high

33

Mar 2026

All-time low

11

Jun 2026

Average rank

22

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
73
—
—
—
Price/Book
34
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
19
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare CRISPR Therapeutics with its peers
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Genfit
PAR:GNFT
32
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cellectis
PAR:ALCLS
19
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Molecular Partners
SWX:MOLN
1
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →